Ivonescimab trial for TNBC (NCT07017673): short film

Name: Ivonescimab trial for TNBC (NCT07017673)
Uploaded: 2026-10-31T20:29:10.204Z
Duration: 1 min 32 s
Description: Ivonescimab trial for TNBC (NCT07017673). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07017673.

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer: a one-minute explainerNCT070176731 min

Ivonescimab trial for TNBC (NCT07017673). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk, nonmetastatic triple-negative breast cancer, at least T1cN0 or any T with N1–N2 disease. ER and PR up to ten percent are allowed; treatment is before surgery.

The idea: ivonescimab targets PD-1 immune suppression and VEGF blood-vessel signaling. Patients receive intravenous ivonescimab, carboplatin, and docetaxel every three weeks for six cycles, then surgery. Researchers check for absence of invasive cancer in breast and nodes, side effects, and longer-term outcomes.

This phase 2 study plans 34 patients. Yuan Yuan leads at Cedars-Sinai; three US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.